Translation of a-t 2021; 51: 6-7
In Brief
Ivermectin (DRIPONIN) against COVID-19?
We are currently receiving a number of inquiries about the benefit of ivermectin (DRIPONIN) against COVID-19. The current interest in the deworming agent and scabies treatment may very much be a result of the Front Line COVID-19 Critical Care Alliance (FLCCC), a group founded by eight American doctors that published an overview in December 2020 describing, among other things, a reduction in mortality as a result of ivermectin and recommending the per os administration to prevent and treat COVID-19. The updated version of the paper that is no longer available (1) includes both references to observational data and 15 studies referred to as randomised (2-16). Their inadequate quality is, however, insufficiently well addressed. Three studies have not been published and the data merely came from the ClinicalTrials.gov study register (2-4). In the vast majority of cases, only preprint publications of the studies without peer review are available (5 13). Some of them are not (5, 6) or only quasi randomised (by means of the date [7] or alternating [11, 14]), or the method remains unclear. Many of the studies are not blinded (2, 4, 7, 9, 11, 14, 15), investigate a maximum of 100 patients (6, 7, 10, 12, 14 16) or investigate ivermectin in combination with other active substances (3, 4, 6, 7, 11). Some of them did not identify any advantages in their primary endpoints (10, 11, 13-15). There is also uncertainty regarding the extent to which unpublished negative studies might change the picture. After consultation with the FLCCC (17), the COVID-19 Guideline Committee of the American National Institutes of Health (NIH) found the data to be insufficient to make a recommendation for or against the use of ivermectin to treat COVID-19 in a current statement. The Committee feels that additional, sufficiently large and well designed clinical studies are necessary (18). We think so, too. -Ed.
| (R = randomized study) | ||
| 1 | KORY, P. et al.: FLCCC Alliance Review, 12 Jan. 2021; http://www.a-turl.de/?k=orbr | |
| R | 2 | SHOUMAN, W.: ClinicalTrials.gov, Aug. 2020; http://www.a-turl.de/?k=uggi |
| R | 3 | MAHMUD, R.: ClinicalTrials.gov, Oct. 2020; http://www.a-turl.de/?k=aimh |
| R | 4 | DE LOS ANGELES PERAL DE BRUNO, M.: ClinicalTrials.gov, Jan. 2021; http://www.a-turl.de/?k=eufr |
| 5 | CADEGIANI, F.A. et al.: medRxiv.org, publ. online 4 Nov. 2020; https://doi.org/10.1101/2020.10.31.20223883 (41 pages) | |
| 6 | SPOORTHI, V., SASANK, S.: International Archives of Integrated Medicine 2020; 7: 177-82 | |
| R | 7 | HASHIM, H.A. et al.: medRxiv, publ. online 27 Oct. 2020; https://doi.org/10.1101/2020.10.26.20219345 (14 pages) |
| R | 8 | NIAEE, M.S. et al.: Research Square, publ. online 24 Nov. 2020; http://www.a-turl.de/?k=amfe (18 pages) |
| R | 9 | ELGAZZAR, A. et al.: Research Square, publ. online 28 Dec. 2020; http://www.a-turl.de/?k=alit (14 pages) |
| R | 10 | CHACCOUR, C. et al.: Research Square, publ. online 7 Dec. 2020; http://www.a-turl.de/?k=alve (20 pages) |
| R | 11 | CHOWDHURY, A.T.M.M. et al.: Research Square, publ. online 14 July 2020; https://doi.org/10.21203/rs.3.rs-38896/v1 (19 pages) |
| R | 12 | BABALOLA O.E. et al.: medRxiv, publ. online 6 Jan. 2021; https://doi.org/10.1101/2021.01.05.21249131 (31 pages) |
| R | 13 | RAVIKIRTI et al.: medRxiv, publ. online 9 Jan. 2021; https://doi.org/10.1101/2021.01.05.21249310 (10 pages) |
| R | 14 | PODDER, C.S. et al.: IMC J. Med. Sci.; 14: 002; http://www.a-turl.de/?k=erle (8 pages) |
| R | 15 | CHACHAR, A.Z.K. et al.: International Journal of Sciences 2020; 9: 31-5 |
| R | 16 | AHMED, S. et al.: Int. J. Infect. Dis. 2020; 103: 214-6 |
| 17 | FLCCC: press release, 15 Jan. 2021; http://www.a-turl.de/?k=noch | |
| 18 | NIH: Statement, 14 Jan. 2021; http://www.a-turl.de/?k=euss |
© arznei-telegramm (Berlin/Germany), January 2021, protected by copyright laws.
Autor: Redaktion arznei-telegramm - Wer wir sind und wie wir arbeiten
Diese Publikation ist urheberrechtlich geschützt. Vervielfältigung sowie Einspeicherung und Verarbeitung in elektronischen Systemen ist nur mit Genehmigung des arznei-telegramm® gestattet.
